Literature DB >> 24986612

Eosinophil shape change and secretion.

Lian Willetts1, Sergei I Ochkur, Elizabeth A Jacobsen, James J Lee, Paige Lacy.   

Abstract

The analysis of eosinophil shape change and mediator secretion is a useful tool in understanding how eosinophils respond to immunological stimuli and chemotactic factors. Eosinophils undergo dramatic shape changes, along with secretion of the granule-derived enzyme eosinophil peroxidase (EPX) in response to chemotactic stimuli including platelet-activating factor and CCL11 (eotaxin-1). Here, we describe the analysis of eosinophil shape change by confocal microscopy analysis and provide an experimental approach for comparing unstimulated cells with those that have been stimulated to undergo chemotaxis. In addition, we illustrate two different degranulation assays for EPX using OPD and an enzyme-linked immunosorbent assay technique and show how eosinophil degranulation may be assessed from in vitro as well as ex vivo stimulation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24986612     DOI: 10.1007/978-1-4939-1016-8_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

1.  Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial.

Authors:  Janet DuBois; Suzanne Bruce; Daniel Stewart; Steven Kempers; Christy Harutunian; Terry Boodhoo; Amy Weitzenfeld; Joan-En Chang-Lin
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-10-15

2.  Metabolic Profiling of Human Eosinophils.

Authors:  Linsey Porter; Nicole Toepfner; Kathleen R Bashant; Jochen Guck; Margaret Ashcroft; Neda Farahi; Edwin R Chilvers
Journal:  Front Immunol       Date:  2018-06-21       Impact factor: 7.561

3.  The anti-parasitic drug miltefosine suppresses activation of human eosinophils and ameliorates allergic inflammation in mice.

Authors:  Eva Knuplez; Melanie Kienzl; Athina Trakaki; Rudolf Schicho; Akos Heinemann; Eva M Sturm; Gunther Marsche
Journal:  Br J Pharmacol       Date:  2021-02-02       Impact factor: 9.473

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.